Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00292552 |
This is a 3 year longitudinal study to identify novel endpoints and compare these with standard measures such as forced expiratory volume in 1 second (FEV1) for their ability to measure and predict COPD (Chronic Obstructive Pulmonary Disease) severity and its progression over time. Control subjects (smokers and never smokers) will be recruited as comparators with the COPD subjects.
Condition |
---|
Chronic Obstructive Pulmonary Disease (COPD) |
Study Type: | Observational |
Study Design: | Prospective |
Official Title: | A Multicentre 3 Year Longitudinal Prospective Study to Identify Novel Endpoints and Compare These With Forced Expiratory Volume in 1 Second (FEV1) for Their Ability to Measure and Predict COPD Severity and Its Progression Over Time |
Ages Eligible for Study: | 40 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Control Subjects - Current/Ex Smokers
Control Subjects - Non-smokers
Exclusion Criteria:
COPD Subjects
Control Subjects
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | SCO104960 |
Study First Received: | February 14, 2006 |
Last Updated: | October 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00292552 |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
eclipse longitudinal |
Lung Diseases, Obstructive Respiratory Tract Diseases Lung Diseases |
Respiration Disorders Disease Progression Pulmonary Disease, Chronic Obstructive |